<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000644755"><TermName>mifamurtide</TermName><TermPronunciation>(mih-FAM-yoor-tide)</TermPronunciation><TermDefinition><DefinitionText>A drug being studied in the treatment of young adults with bone cancer that has gotten worse or come back. Mifamurtide activates certain types of white blood cells and helps the immune system kill cancer cells. It is a type of immunostimulant. Also called L-MTP-PE, MEPACT,  and muramyl tripeptide phosphatidylethanolamine.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000726269" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;mifamurtide&quot;" language="en" id="_3"/><MediaLink ref="CDR0000726268" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;mifamurtida&quot;" language="es" id="_4"/><SpanishTermName>mifamurtida</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento en estudio para el tratamiento de adultos jóvenes con cáncer de hueso que ha empeorado o ha reaparecido. La mifamurtida activa ciertos tipos de células sanguíneas y ayuda al sistema inmunitario a eliminar las células cancerosas. Es un tipo de inmunoestimulante. También se llama L-MTP-PE, MEPACT,  y muramil tripéptido fosfatidiletanolamina.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-11-09</DateFirstPublished></GlossaryTerm>
